Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.
暂无分享,去创建一个
M. Atkins | M. Hurwitz | B. Rini | D. McDermott | H. Hammers | M. Ornstein | N. Shah | C. Mantia | Anita Gul | T. Stewart | Kimberly D. Allman | Emily Stern Gatof | Y. Long | Neil J. Shah
[1] B. Melichar,et al. Tailored immunotherapy approach with nivolumab in advanced renal cell carcinoma (TITAN-RCC) , 2019, Annals of Oncology.
[2] T. Powles,et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.
[3] R. Motzer,et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.
[4] Bohuslav Melichar,et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.
[5] E. Plimack,et al. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] A. Ravaud,et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[7] R. Raman,et al. Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review , 2015, BioMed research international.
[8] J. Wolchok,et al. Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo , 2015, The Journal of Immunology.
[9] F. Hodi,et al. Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1 , 2012, Clinical Cancer Research.
[10] E. Wherry. T cell exhaustion , 2011, Nature Immunology.
[11] J. Bluestone,et al. Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways , 2008, Immunological reviews.
[12] S. Steinberg,et al. High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma , 2008, Cancer.
[13] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[14] R. Motzer,et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.